


# MURTY PHARMACEUTICALS, INC. (MPI)

---

## CAPABILITIES STATEMENT



---

**518 CODELL DRIVE, LEXINGTON, KY 40509**  
**Email: [info@mpirx.com](mailto:info@mpirx.com)**  
**Tel: (859) 266-2446, Fax: (859) 266-6976**

## **BACKGROUND AND FACILITIES**

---

### **BACKGROUND**

President and Scientific Director, Dr. Ram Murty founded Murty Pharmaceuticals, Inc. (MPI) in 1995. Helping to establish and implement Good Manufacturing Practices Regulations (GMPs) since their inception in 1970s and through the 1980s, Dr. Murty has continued research, technology, and commercial based objectives for the NIH as well as the pharmaceutical industry. As a result, during the past decade, MPI was established with the defined goals to undertake high quality research projects covering New Chemical Entities from formulation through clinical supply phases as well as devising innovative delivery systems. Furthermore, the organization has recently established commercial scale manufacturing for solid oral dosage forms. This will provide MPI's clients and partners the option for a single source stop for research and development phases through commercialization.

### **FACILITIES**

MPI's 27,000 square foot facility is located in Lexington, Kentucky, USA. The facility is FDA approved for commercial scale manufacturing and maintains appropriate licenses with the DEA and the State Pharmacy Board. The facility comes equipped with a state-of-the-art laboratory containing a variety of elaborate and sophisticated instrumentation, two processing and manufacturing suites, secure and non-secure warehouse space, office space, and a fully automated packaging line.

## SERVICES

---

MPI offers a wide spectrum of services and expertise in scientific, professional, technical, manufacturing, quality control, and regulatory fields in compliance with applicable cGMP/GLP regulations. Services include formulation development, drug delivery design, analytical method development/ validation, drug stability assessment, clinical and commercial scale manufacturing, labeling, packaging, and shipping. The company also possesses state-of-the-art supercritical fluid (SCF) units for small-scale isolation, extraction, and purification of drug moieties. Finally, MPI provides documentation and regulatory support for DMF preparations and IND, NDA, and ANDA submissions.

### **Testing of Active Pharmaceutical Ingredients (API's) and Excipients**

Comprehensive testing consists of chromatographic, spectral, thermogravimetric, differential scanning calorimetric, and LC/MS techniques.

### **Pre-formulation Studies**

To develop dosage forms to achieve enhanced solubility, sustained delivery, enhanced stability, targeted delivery, improved bioavailability, acceptability for specialized use, and administration for alternate routes, systematic pre-formulation studies are conducted at MPI facilities. Listed below are some of the critical tests that MPI scientists can perform:

Solubility profile	Partition coefficient	pH rate profile	Bulk density
Polymorphism	Particle size distribution	Flow properties	Stability
Dissolution	Drug-excipient interaction	Log pKa	TGA/DSC

### **Development of Dosage Forms**

Oral dosage forms (conventional and extended release) - Tablets, Capsules, Liquids

Parenterals - Liquid and Lyophilized

Semi-solids - Gels, Ointments, Creams

Rectal/Vaginal - Suppositories, Solutions, Ointments

### **Drug Delivery Systems**

MPI developed proprietary, patented platforms for specific clients and partners, including the following:

Microencapsulation    Controlled release    Sublingual    Transdermal Gels

## **Analytical Methods**

LC/MS

High performance liquid chromatography (HPLC)

Gas chromatography

UV/Visible spectrophotometry

Log pKa/Log P Determination

Supercritical Fluid Separations

## **Analytical Method Development**

Raw material testing

Packaging material testing

Stability indicating assay

Dissolution testing

Cleaning residues - swab and rinse samples

Residual organic volatiles

## **Analytical Method Validation**

Recovery

Accuracy

Precision

Repeatability

System suitability

Specificity- forced degradation studies

Solution stability

Ruggedness

Robustness

## **Stability Assessment**

Stability protocols follow current practices incorporating ICH guidelines, which are implemented to determine the stability of the finished product in the proposed container-closure system. MPI's facility is equipped to conduct stability studies under the following storage conditions, but can meet other, more specialized conditions upon customer request.

Stability Conditions:

Long-term:  $25^{\circ} \pm 2^{\circ}\text{C}$ ,  $60\% \pm 5\%$  RH for 3, 6, 9, 12, 18, 24, and 36 months

Intermediate:  $30^{\circ} \pm 2^{\circ}\text{C}$ ,  $60\% \pm 5\%$  RH /  $65\% \pm 5\%$  RH for 1, 2, 3, and 6 months

Accelerated:  $40^{\circ} \pm 2^{\circ}\text{C}$ ,  $75\% \pm 5\%$  RH for 1, 2, 3, and 6 months

Accelerated:  $50^{\circ} \pm 2^{\circ}\text{C}$ ,  $75\% \pm 5\%$  RH for 1, 2, 3 months

A reference sample will be stored under ambient conditions unless specified otherwise

Freeze-thaw ( $-20^{\circ}\text{C}$  to ambient)

Photostability

## **Manufacturing Process Development and Validation**

Liquid orals

Tablets

Capsules

Semi-solids (gels, lotions, creams)

Solid dosage forms (suppositories)

Parenteral (both liquid and lyophilized)

## **Clinical & Commercial Manufacturing and Re-packaging**

Solid Oral Dosage Forms : The firm has all necessary equipment for manufacturing solid oral dosage forms, including tablets and capsules of various sizes. Additionally, MPI has the necessary infrastructure and experience for the storage, distribution, and documentation for clinical supplies intended for all phases of NDA. Dedicated employees monitor all activities for clinical supplies and commercial batches.

For other dosage forms, including parenterals and semi-solids, the firm has capabilities to manufacture pilot batches. For production batches, outside sources with demonstrated compliance profiles and cost effective budgets are selected. MPI coordinates scale-up and technology transfer activities to maintain continuity as well as to provide overall assurance for meeting delivery schedules.

## **Documentation and Regulatory Submission Support**

The firm has extensive experience in DMF and CMC preparation, for providing regulatory support for IND, NDA, and ANDA submissions.

## **Consultation**

Product/process development

Facility design, development, and validation

Evaluation of pharmaceutical systems and equipment

Scale-up and technology transfer

# INSTRUMENTATION AND EQUIPMENT

---

## Laboratory Instruments

### LC/MS

LC-MS Agilent 1100 HPLC with 1100  
LC/MSD VL System

### High Pressure Liquid Chromatography

HP 1050 with DAD and Autosampler  
HP 1100 with DAD and Autosampler (4)  
HP 1100 with VWD and Autosampler (3)  
Waters Alliance 2690 with-  
PDA/ECD/ fluorescence  
Waters Alliance 2695 with PDA 2996 (with  
automated analytical method development  
capability)

### Semi-Preparatory HPLC (FPLC)

Dionex Auto Summit System with DAD

### Spectrophotometry

Perkin-Elmer Spectrophotometer 1000 FTIR  
Beckman DU 64 UV/VIS  
Beckman DU 520 UV/VIS

### Elemental-Metal Analysis

Perkin-Elmer 3300 Atomic Absorption

### Dissolution

Vankel -6 flasks  
Hanson-Research-6 Biodis  
Hanson-Research-6 flasks  
Hanson-Research-8 flasks  
Hanson Research Autosampler

Diffusion/Permeation System  
Franz (vertical) skin diffusion (6 cells)  
Valia-Chin lateral skin permeation (9 cells)

### Friabilator

Pharmatest single drum  
Electrolab Tablet Friabilator

### Stability/Storage Chambers

Photostability chamber (ICH)  
Long-term storage (25°C / 60% RH)  
Intermediate storage (30°C / 60% RH)  
Intermediate storage (30°C / 65% RH)  
Accelerated storage (40°C / 75% RH)  
Accelerated storage (50°C / 75% RH)  
Refrigerators (8) [2-8°C]  
Incubator (8-15°C)  
Walk-in-Cooler (2-8°C), 630 Cu. Ft. (2)

Freezers (10) [-10 and -70°C]

### Classical and Wet Chemistry

Melting point apparatus  
Analytical balance (3)  
Microbalance  
Centrifuge: desktop and ultracentrifuge  
pH meter (2)  
Oxygen meter  
Refractometer  
Brookfield Viscometer  
Muffle Furnace  
Kruss P1000 Polarimeter

### Gas Chromatography

HP 6890 with FID/TCD and Autosampler  
HP 5890 with FID and Autosampler

### Calorimetry / Gravimetry / PQ / pKa

Perkin-Elmer DSC-6  
Perkin-Elmer TGA-6  
PCA-200 with D-PAS

### Moisture Analysis

Karl-Fischer DL-38 titrimer  
Denver IR 200

### Particle Size Analysis

Malvern 2C autosizer  
Hiac Royco counter  
Bausch and Lomb microscope  
Olympus SZX60 Stereo Microscope with -  
Camera

### Disintegration

Vankel single bath (2)  
Electrolab Tablet Disintegration Tester -  
Model -D-2AL

### Specialized Storage Facility

DEA-Licensed Secure Controlled Substance  
Storage

### Miscellaneous

NANO-pure water unit  
Solid phase extraction unit  
Sonicator bath (2)  
Digital Torque Tester

### Automatic Titrator

Mettler Toledo DL 53

## Pharmaceutical Processing Equipment

### Tabletting/Capsules

Tablet press – 16  
Tablet press – 27 stations (2)  
Tablet hardness tester (2)  
Tablet de-burring/de-dusting machine  
Dust extractor machine  
Semi-automatic capsule filling machine  
Manual capsule filling machine (3)  
Tablet tool cleaning maintenance kit  
Vanguard Friability Tester  
Logan HDT-300 Hardness Tester  
Vanguard Tablet Hardness Tester  
Vanguard Disintegration Tester  
Vanguard Capsules Polishing and Sorting Machine  
Single Roller Band Sealing Machine

### Liquid Mixing

Agitator (0.5 HP)  
Homogenizer  
Colloidal Mill

### Drying

Tray Drier (1)  
Fluid bed drier – 10 Kg  
Oven (2)  
Gansons Fluid Bed Drier – 60kg

### Extractor

Supercritical Fluid Extractor, 1L  
Supercritical Fluid Extractor, 2X5 L

### Distillation

Brinkmann R220, 20L Rotary Evaporator

### Mixing & Blending

Double cone - 5 kg  
PK blender (5 ft<sup>3</sup>)  
Drum blender – 20L  
V-blender – 20L  
Kitchen Aid Mixer 5L (2)  
Hobart – 30, 40 qt and 60 qt  
Ribbon (Mass) mixer  
Octogonal Blender – 400L  
Gansons Planetary Mixer – 100L

### Milling

Centrifugal mill (Retsch)  
Fitz mill (2)  
Multimill (3)

### Pelletization

Spherodizer  
Marumerizer

### Sifting

Sifter (30")  
Sieves  
Sieve Shaker

### Coating

Coating Blower  
48" Coating pan (2)  
12" Coating pan  
Coating spray system  
Ganscoater GAC 250  
Ganscoater GAC 600  
Ganscoater GAC 1200

### Packaging

Blister-packing machine  
Pharmapack counting machine  
Hispack Counters (2)  
CVC Bottle Packaging Line

### Ointment Filling Machine

Ointment/tube filling machine  
Ointment/tube crimping machine

### Granulator

Rotary granulator  
Rapid mixing granulator, HSMG5, 5L  
Rapid mixing granulator, HSMG50, 50L

### Parenteral Filling

Vial filling machine  
Ampule filling and sealing machine (2)  
Manual ampule sealing machine  
Lyophilizer  
Masterflex peristaltic pump  
Dry heat sterilizer  
Power washer  
NANO-pure water unit  
Laminar airflow cabinets  
Steam sterilizer

### Miscellaneous

Balance (7)  
Air Compressors (3)  
Platform balance (2)  
Refrigerated incubator  
Reposograph  
Bulk density tester  
Culligan – USP Purified Water System

# QA / QC PROCEDURES

---

## **Compliance with GMP Requirements**

The firm is committed to maintaining a compliance profile with all applicable regulations including cGMPs, GLPs, State Board of Pharmacy requirements, and DEA regulations.

## **Equipment Maintenance**

All major processing equipment and laboratory instrumentation are maintained and calibrated by in-house personnel and, where necessary, by authorized representatives under appropriate service contracts.

## **Inventory Controls**

The bulk drug substances and excipients received at MPI are assigned a lot number, quarantined, sampled, tested, and released after verifying conformance with established specifications. An inventory control system is maintained to determine the traceability, rotation of stock, and reassay schedules, etc. Similarly, distribution records are retained with appropriate documentation in accordance with cGMP regulations.

## **Validation Commitments**

An integrated validation approach for various processes and procedures has been established. In addition, particular attention is focused on cleaning procedures to minimize cross contamination potentials during the processing, handling, and packaging of drug products.

## **Packaging and Labeling**

MPI complies with applicable cGMPs found in 21 CFR Parts 210 and 211 for packaging and labeling. All packaging components are received from selected vendors and assigned a lot number for each shipment to ensure traceability. For each shipment/component, inventory and usage logs, together with pertinent certification documents, are reviewed and retained.

MPI clients send label copies for review and approval. After approval, the labels are printed and controlled in a manner consistent with cGMP requirements. An inventory is maintained and reconciliation is performed.

## **Shipments**

After completing all quality control testing and conformance verifications, the products are released for distribution to clinical or client specified sites. Upon completion of a project, a production report is forwarded for review. The report includes a description of the manufacturing procedures, quality control test methods, results, and batch accountability measures employed. After receiving release authorization and shipping instructions, shipments are arranged through an insured, 24-hour delivery service. Accurate inventory, distribution records, and receipts for shipment are retained in files to ensure complete traceability.



## **Quality Control Testing**

In-process quality control tests include materials at various stages of manufacturing. Finished product testing is formalized in conjunction with the project officers identified by MPI's clients.

Quality control tests include integrity, appearance, weight variation, disintegration, dissolution, moisture content, potency, limit impurities, and other tests designed to evaluate conformance with product specifications. When necessary, qualified laboratories are utilized to undertake sterility, endotoxin, and other specialized tests as required pursuant to compendial procedures. All data is reviewed to verify conformance with product specifications prior to release. Any unexplained deviations are investigated, and the results are documented in master batch records.

## **Documentation**

MPI has implemented a documentation system, which enables complete traceability. Manufacturing and control data are devised as per cGMP regulations and retained in a manner which renders easy retrieval. Complete details of master formula instructions and test results are formalized in a batch record system, which covers batch yields, accountability, and distribution. Representative samples are retained from each batch and documented. Any complaints/inquires pertaining to a specific lot are documented and thoroughly investigated. Results and summaries of all investigations are retained in appropriate files.

## **Confidentiality and Security**

The organization is aware of the confidential nature of research

investigations. All personnel engaged in the proposed investigations are instructed to support the firm's policies and the confidential nature of the work. All employees, prior to entering employment, execute a confidentiality agreement. The firm monitors the overall effectiveness of this pursuit.

An outside security firm monitors the entire facility and access to the facility is controlled. Unauthorized personnel are restricted from entering the premises in view of the highly selective and classified information that is being handled for various clients including Federal Government contracts. Dedicated rooms with electronic monitors are built within the facility for the storage and control of drug substances. In addition, the firm has provided storage space for highly classified information to prevent unauthorized distribution, and to maintain confidentiality. The firm always ensures that it has no conflicts with other commitments and/or projects.